NewsRoom Articles - Page 42 of 214

WednesdayApr 10, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients AVERSA technology can be incorporated into any transdermal patch The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch In April 2024, the company announced it had received a contract manufacturing order from…

TuesdayApr 09, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…

MondayApr 08, 2024 10:00 am

Researchers Link Hormone Treatments to Heightened Risk of Brain Tumors

Scientists at the National Agency for Medicines and Health Products Safety in France recently linked the use of hormone treatments by women to a heightened risk of women developing benign brain tumors. During their research, they determined that prolonged use of some progestogen drugs was associated with a higher risk of meningioma. This sentiment isn’t shared by all, however, with one leading expert noting that while the risk of meningioma was higher in women who took the drugs for more than one year, the finding need not worry present or past users as heightened risk remained small. Meningiomas are common…

FridayApr 05, 2024 10:30 am

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

A Brookings Institution report indicates significant racial disparities in access to health coverage and in health outcomes Astiva Health is focused on reshaping the landscape of personalized and comprehensive healthcare The company carefully considers needs of its members, creates plans that feature cultural strategies for diverse ethnic groups In a world where racial disparities still run rampant in many ways, including health coverage and outcomes, Astiva Health is focused on meeting the healthcare needs of underserved populations. The company recognizes the diverse challenges within key communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions. “In the…

FridayApr 05, 2024 10:00 am

Google Develops AI System to Leverage Sound in Detecting Lung Ailments

Health acoustic sounds contain useful health signals that have the potential to aid in health monitoring as well as disease diagnosis. Recently, scientists at Google Research, in collaboration with researchers at Zambia’s Center of Infectious Disease Research, developed an AI system that can use coughing sounds to diagnose lung disease. The system, called Health Acoustic Representations (HeAR), is available as a preprint on arXiv. The investigators started working on the system after healthcare professionals reported that over time, they had learned to tell which patients had coronavirus by how their coughs sounded. For their study, they used an approach similar…

WednesdayApr 03, 2024 10:00 am

Spotlight on Disparities in Pediatric Healthcare Access

As of 2019, congenital heart defects affected roughly 1.3 million individuals in America. Mild heart defects are shown to present in at least eight of every one thousand babies. Experts believe that about one in four infants born with these defects need intervention in their first 12 months of life to survive. Now, new research has determined that children in heavily polluted areas classified as economically and socially deprived were almost 50% more likely to suffer from congenital heart defects as compared to those from less polluted and less deprived areas. This comes after research by the American Heart Association…

TuesdayApr 02, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R) CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating Certain apolipoproteins found on the nanocrystals' surface, which aid in crossing the blood-brain barrier (“BBB”), were identified, suggesting an enhanced delivery mechanism into the brain The findings enrich the understanding of CNM-Au8's mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company…

MondayApr 01, 2024 10:00 am

Prenatal Exposure to Caffeine and High-Fat Diets Heighten Autism Risk in Rodent Models

A new study has found that caffeine exposure during pregnancy and a high-fat diet following delivery considerably heightens the risk of autism-like behaviors, as observed in rodent models. Autism spectrum disorder is a developmental disorder that influences how individuals interact, behave, learn and communicate. Children with this condition may have trouble with social interactions as well as display repetitive behaviors, among other symptoms. Given that caffeine consumption and high-fat diets are widespread, it is important to understand possible risk factors and develop strategies to prevent the disorder’s development. For their study, the researchers divided pregnant rats into two groups, one…

MondayApr 01, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the…

ThursdayMar 28, 2024 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Researchers Link Hormone Treatments to Heightened Risk of Brain Tumors

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

Google Develops AI System to Leverage Sound in Detecting Lung Ailments

Spotlight on Disparities in Pediatric Healthcare Access

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

Prenatal Exposure to Caffeine and High-Fat Diets Heighten Autism Risk in Rodent Models

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search